



Sulfated liposaccharides inspired by telomerase inhibitor axinelloside A[☆]

Jie Guang, Zachary A. Rumlow, Lauren M. Wiles, Sloane O'Neill, Maciej A. Walczak^{*}

Department of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309, USA

ARTICLE INFO

Article history:

Received 10 October 2017

Revised 7 November 2017

Accepted 16 November 2017

Available online 20 November 2017

Keywords:

Liposaccharides
Sulfated saccharides
Telomerase
Sulfate esters

ABSTRACT

Sulfated liposaccharides are known inhibitors of telomerase and here we describe the synthesis of a series of sulfated liposaccharides inspired by the natural product axinelloside A, reported to act as an inhibitor of human telomerase. We established a robust and scalable synthetic route to galactosyl liposaccharides capitalizing on a series of regioselective acylation reactions with 2-decenoic acid and imidazolium sulfate esters.

© 2017 Elsevier Ltd. All rights reserved.

Introduction

Inhibition of telomerase activity offers potential therapeutic benefits in the treatment of cancer.¹ This assertion is based on the fact that >85% of human cancers express telomerase but this enzyme is not present in most somatic cells.² It has been recently reported that sulfated saccharides, specifically axinelloside A,³ display potent inhibitory activity against human telomerase *in vitro*. While the structural and mechanistic details of how these saccharides interact with the enzyme and which components of the sulfated saccharide are critical for the binding are not known, the sulfated small molecule nonetheless offers a promising strategy to target telomerase.

Telomeres are specialized caps attached at the end of human chromosomes consisting of 1000–2000 non-coding repeats of TTAGGG DNA sequence.⁴ The main role of these tandem repeats is to protect DNA from undesired degradation and repair, and a specialized enzyme, telomerase, maintains the integrity of the telomeres. Telomerase is a holoenzyme composed of two units: hTERT (human Telomerase Reverse Transcriptase) and hTR (human Telomerase RNA). The RNA component acts as a template (5'-CUAACCUAA-3') for the synthesis of telomere repeats which is catalyzed by the reverse-transcriptase subunit. Given the importance of telomerase in maintaining the viability of cancer cells and its potential as a therapeutic target, numerous studies have aimed

at the identification of a viable telomerase inhibitor.⁵ The recent approaches towards telomerase inhibition focused on inhibition of hTERT and includes small molecules (BIBR1532),⁶ anti-sense oligonucleotides (GRN163L),^{7–13} immunotherapeutics (hTERT peptides used as epitopes to induce CD4+ and CD8+ cells),¹⁴ and gene therapy (telomelysin¹⁵). Numerous other approaches focused on stabilizing the G-quadruplex structure, preventing access of telomerase to telomeres (telomestatin,¹⁶ BRACO19¹⁷), and targeting telomerase-associated complexes (inhibitors of HSP90 such as geldanamycin¹⁸ and curcumin¹⁹) have been reported as well. Currently, the most promising candidate (GRN163L, Imetelstat) has undergone a total of 12 Phase I/II clinical trials targeting multiple myeloma,²⁰ myelofibrosis, essential thrombocythemia,²¹ and lymphoma (more recently, PII/III in patients with myelodysplastic syndrome). GRN163L is a lipidated oligonucleotide thiophosphate acting as an antagonist of hTERT.


Axinelloside A (**1**), a sulfated oligosaccharide, was isolated from the marine sponge *Axinella infundibula*³ and the structure of this metabolite was established by extensive 1D/2D NMR and MS studies. The important features of the proposed structure of **1** are: (a) the presence of four fatty acid residues, including three unsaturated (*E*)-2-hexadecenoic esters, (b) *scyllo*-inositol residue (unit A) located at the eastern terminus of axinelloside A,²² and (c) 19 sulfate groups spread along the chain of the natural product. All but one glycosidic linkages are in a 1,2-*cis* glycosidic configuration, rendering the chemical synthesis of this molecule a formidable task. The inhibitory activity of axinelloside A was evaluated by the Telespot assay²³ and **1** showed an IC₅₀ of 2.0 µg/mL with isolated human telomerase. Axinelloside A belongs to a larger group

[☆] This research was supported by the University of Colorado.

^{*} Corresponding author.


E-mail address: maciej.walczak@colorado.edu (M.A. Walczak).

of sulfated natural products that inhibit telomerase. For example, dictyodendrins A-E, which are polycyclic sulfated alkaloids, show appreciable inhibitory activities.²⁴ A special sub-category of sulfated lipids involves sulfoquinovosyl diacylglycerols (SQDGs) known to inhibit telomerase as well as DNA polymerase.²⁵ Subsequently these saccharides were found through computational modeling to be also inhibitors of HIV-RT.²⁶ Recently, Gademann and coworkers tested a series of D-glucose derivatives of 6-sulfonic acid (Na⁺ salt) and glycolipid units which proved to be telomerase inhibitors.²⁵ In addition to the natural product, a focused library of analogs was prepared through chemical synthesis and tested using the Telespot assay and the inhibitory activity of the natural product was improved by the incorporation of a biphenyl acid chain (IC₅₀ 11 mM). Taken together, liposaccharides with a varying number of sulfate groups represent a promising class of small molecule telomerase inhibitors, and here we present a synthetic strategy to prepare mono- and disulfate esters of D-galactose lipid derivatives.



Scheme 1.

Esterification of **6** with 2-hexadecenoic acid **7** provided diester **8** in 98% isolated yield. We have also tested alternative methods for the introduction of the unsaturated groups such as double acetylation with acryloyl chloride followed by metathesis with Grubbs II catalyst and 1-pentadecene, but this sequence was significantly less yielding and resulted only in ~20% of the product **8**. The removal of the acetal group required some experimentation and typical conditions (AcOH, THF/H₂O; TsOH/H₂O; TfOH/H₂O)




Results and discussion

The western fragment of axinelloside A **1** contains a D-galactose unit modified with two identical fatty acid chains at C2 and C6 and two sulfate groups on C3 and C4 (residue K). We postulated that this fragment of axinelloside A may contribute significantly to the inhibitory activity because similar sulfated molecules with lipid groups were reported to act as telomerase inhibitors on their own (mM concentration range).²⁵ However, this study focused only on sulfonic acids, which may behave similarly to sulfate monoesters but have higher physiological stabilities. Based on this hypothesis, we aimed to prepare the galactose fragment K with two unsaturated acids at positions C2 and C6 before installing two sulfate monoester groups at C3 and C4. This study allows for the evaluation of various conditions for the installation of the ester groups and, more importantly, will establish a robust scheme for the introduction of sulfate groups.


The initial investigations were aimed at evaluating whether the D-galactose residue K can be stereoselectively installed with the correct 1,2-*cis* anomeric configuration. In the context of this question, we elected to prepare the methyl glycoside **4**, which was accessed from the anomeric alcohol **4** and cyclic phosphonium anhydride under previously reported conditions.²⁷ Thus, alcohol **2** was pre-activated with phosphonium salt **3** formed *in situ* from triflic anhydride and DPPBO₂ (1,4-bis(diphenylphosphino)butane dioxide) in the presence of 2,4,6-tri-*tert*-butylpyridine. After 30 min at 0 °C, the nucleophile (MeOH) was added and the reaction was continued for additional 2 h. The methyl glycoside **4** was isolated in 89% and α:β > 95:5. The product of this reaction was then advanced to tetraol **5** by removal of all benzyl groups and conversion into 3,4-dimethyl acetal **6** under the previously reported conditions²⁸ (Scheme 1).

resulted in decomposition of the substrate. However, we found that In(III) salts²⁹ were compatible with the sensitive α,β-unsaturated esters and the exposure of **8** to 4 equiv of InCl₃³⁰ resulted in a clean removal of the acetal group without undesired scrambling of the anomeric configuration and degradation of the unsaturated bis-esters.

At this stage, the installation of two sulfate groups was in place.³¹ A set of conditions using various stable SO₃ sources known to directly convert alcohols into sulfate monoesters (SO₃·Et₃N, SO₃·pyridine, SO₃·DMF in MeCN at rt and 40 °C) resulted in decomposition of the material, most likely due to the acidic nature of the reagents. Efforts to buffer the reaction mixture with inorganic bases (NaHCO₃, K₂CO₃, K₃PO₄, NaOAc) and soluble pyridine-based additives (pyridine, 2,6-lutidine, 2,4,6-tri-*tert*-butylpyridine) were also unsuccessful, resulting in either no reaction or decomposition. The deterioration of (oligo)saccharide material in reactions with SO₃ sources has been reported because these conditions often require elevated temperatures and eventually lead to a highly acidic environment incompatible with O-glycosides. The introduction of two sulfated groups could be accomplished, however, by applying a two step-protocol involving protected imidazolium salt of 2,2,2-trichloroethyl sulfate monoester salt **8** described by Taylor.^{32–36} Thus, double esterification of **7** with **8** and 1-methylimidazole at room temperature afforded 42% of D-galactose derivative **9**. The remainder of the material was either a mixture of mono-protected galactose isomers, and addition of excess of **8** did not result in improved yields and only complicated the purification. We have also investigated other nucleophilic additives which could facilitate the esterification of the diol **7** (DMAP, pyridine, 1*H*-imidazole, trialkyl and triaryl phosphines) and we found that without 1-methylimidazole, the transfer of the sulfate group was minimal (<10%) even after extended reaction times (2 days) and heating



Scheme 2.




Scheme 3.

(CH_2Cl_2 or MeCN, reflux). The 2,2,2-trichloroethyl groups were removed using metallic zinc and ammonium formate to afford sulfate ester **10** in 81% yield as an oil, which was purified by flash chromatography on silica gel with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ and ammonium hydroxide as an eluent without deterioration of the labile sulfate groups (Scheme 2).

Because the role of the unsaturated ester groups in axinelloside A (Michael acceptors) has not been previously studied, we prepared bis-ester **15** containing two saturated esters via a direct

hydrogenation of **9** (Scheme 3). We found that the overall yield of this sequence could be improved if the hydrogenation reaction was conducted with the diol **9** as opposed to a conversion of sulfated ester **12** into **15**, which resulted in the removal of both sulfate groups. Finally, asymmetrical monoester **19** was synthesized using a set of reactions presented in Scheme 4. The *D*-galactose **16** protected at position 6' was converted into a sulfate ester **18** in a sequence of four reaction followed by liberation of the sulfate ester with metallic zinc. Interestingly, the acetal group could be cleanly



Scheme 4.

removed in the presence of a single unsaturated ester with TFA without deterioration of the material.

Some notable observations regarding the synthesis and stability of sulfated monosaccharides can be summarized as follows: (a) the sulfate esters are stable to mild acidic (AcOH) and basic conditions (NaHCO_3 , KHCO_3) but undergo decomposition if exposed for a prolonged time to a strongly basic ($\text{pH} > 9$) environment; (b) the lipidated saccharides are soluble in organic solvents (MeOH, DMSO, DMF) and partially soluble in water; (c) the sulfated monoester **16** retains its originally placed ester groups for ca. six months in a neat form at room temperature, and the sulfate groups are stable to chromatographic purifications; and (d) the liposaccharides obtained in the form of an ammonium salt can be stored indefinitely at -20°C .

Conclusions

In summary, we have described a convergent and scalable synthesis of the sulfated D -galactosyl liposaccharides corresponding to the K fragment of axinellin A. This study establishes a synthetic sequence for the preparation of a telomerase inhibitor and related sulfated oligosaccharides and outlines the key steps for the optimal synthetic outcome. Further studies evaluating the sulfated analogs as potential telomerase inhibitors will establish the importance of the D -galactose residue in **1** for its inhibitory potency.

Conflict of interest

The authors declare no competing financial interest.

References

- Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. *Cancer Treat Rev*. 2013;39:444–456.
- Mocellin S, Pooley KA, Nitti D. Telomerase and the search for the end of cancer. *Trends Mol Med*. 2013;19:125–133.
- Warabi K, Hamada T, Nakao Y, et al. Axinellin A, an unprecedented highly sulfated lipopolysaccharide inhibiting telomerase, from the marine sponge, *Axinella infundibula*. *J Am Chem Soc*. 2005;127:13262–13270.
- Cong Y-S, Wright WE, Shay JW. Human telomerase and its regulation. *Microbiol Mol Biol Rev*. 2002;66:407–425.
- Harley CB. Telomerase and cancer therapeutics. *Nat Rev Cancer*. 2008;8:167–179.
- Damm K, Hemmann U, Garin-Chesa P, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. *EMBO J*. 2001;20:6958–6968.
- Di Maio M, Morabito A, Piccirillo MC, et al. New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. *Expert Opin Invest Drugs*. 2010;19:1503–1514.
- Gryaznov S, Asai A, Oshima Y, et al. Oligonucleotide $\text{n}3'\text{-}\rightarrow\text{p}5'$ phosphoramidates and thio-phosphoramidates as potential therapeutic agents. *Chem Biodivers*. 2010;7:477–493.
- Hashizume R, Gupta N. Telomerase inhibitors for the treatment of brain tumors and the potential of intranasal delivery. *Curr Opin Mol Ther*. 2010;12:168–175.
- Ouellette MM, Wright WE, Shay JW. Targeting telomerase-expressing cancer cells. *J Cell Mol Med*. 2011;15:1433–1442.
- Roth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L)-telomerase-based cancer therapy. *Recent Res Cancer Res*. 2010;184:221–234.
- Akiyama M, Hideshima T, Shammas MA, et al. Effects of oligonucleotide $\text{N}3'\text{-}\rightarrow\text{P}5'$ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. *Cancer Res*. 2003;63:6187–6194.
- Gryaznov S, Asai A, Oshima Y, et al. Oligonucleotide $\text{N}3'\text{-}\rightarrow\text{P}5'$ thio-phosphoramidate telomerase template antagonists as potential anticancer agents. *Nucleosides Nucleotides Nucleic Acids*. 2003;22:577–581.
- Nava-Parada P, Emens LA. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. *Curr Opin Mol Ther*. 2007;9:490–497.
- Nemunaitis J, Tong AW, Nemunaitis M, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (Telomelysin) for various solid tumors. *Mol Ther*. 2009;18:429–434.
- Kim M-Y, Vankayalapati H, Shin-ya K, Wierzbka K, Hurler LH. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. *J Am Chem Soc*. 2002;124:2098–2099.
- Zhou G, Liu X, Li Y, et al. Telomere targeting with a novel G-quadruplex-interactive ligand BRACO-19 induces T-loop disassembly and telomerase displacement in human glioblastoma cells. *Oncotarget*. 2016;7:14925–14939.
- Villa R, Folini M, Porta CD, et al. Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. *Carcinogenesis*. 2003;24:851–859.
- Khaw AK, Hande MP, Kalthur G, Hande MP. Curcumin inhibits telomerase and induces telomere shortening and apoptosis in brain tumour cells. *J Cell Biochem*. 2013;114:1257–1270.
- Shammas MA, Koley H, Bertheau RC, et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. *Leukemia*. 2008;22:1410–1418.

21. Baerlocher GM, Burington B, Snyder DS. Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis. *N Engl J Med.* 2015;373:2580.
22. Rodriguez J, Walczak MA. Synthesis of asymmetrically substituted scyllo-inositol. *Tetrahedron Lett.* 2016;57:3281–3283.
23. Cristofari G, Reichenbach P, Regamey P-O, et al. Low- to high-throughput analysis of telomerase modulators with Telospot. *Nat Meth.* 2007;4:851–853.
24. Warabi K, Matsunaga S, van Soest RWM, Fusetani N. Dictyodendrins A–E, the first telomerase-inhibitory marine natural products from the sponge dictyodendrilla verongiformis1. *J Org Chem.* 2003;68:2765–2770.
25. Makhlof Brahmi M, Portmann C, D'Ambrosio D, et al. Telomerase inhibitors from cyanobacteria: isolation and synthesis of sulfoquinovosyl diacylglycerols from microcystis aeruginosa PCC 7806. *Chem Eur J.* 2013;19(14):4596–4601.
26. Oda M, Ueno T, Kasai N, et al. Inhibition of telomerase by linear-chain fatty acids: a structural analysis. *Biochem J.* 2002;367:329–334.
27. Dyapa R, Dockery LT, Walczak MA. Dehydrative glycosylation with cyclic phosphonium anhydrides. *Org Biomol Chem.* 2017;51:15.
28. Rashid A, Mackie W, Colquhoun IJ, Lamba D. Novel Synthesis of monosulphated methyl α -D-galactopyranosides. *Can J Chem.* 1990;68:1122–1127.
29. Gregg BT, Golden KC, Quinn JF. Indium(III) trifluoromethanesulfonate as an efficient catalyst for the deprotection of acetals and ketals. *J Org Chem.* 2007;72:5890–5893.
30. Ranu BC, Jana R, Samanta S. A simple, efficient and general procedure for acetalization of carbonyl compounds and deprotection of acetals under the catalysis of indium(III) chloride. *Adv Synth Catal.* 2004;346:446–450.
31. Simpson LS, Widlanski TS. A comprehensive approach to the synthesis of sulfate esters. *J Am Chem Soc.* 2006;128:1605–1610.
32. Ingram LJ, Taylor SD. Introduction of 2,2,2-trichloroethyl-protected sulfates into monosaccharides with a sulfuryl imidazolium salt and application to the synthesis of sulfated carbohydrates. *Angew Chem Int Ed.* 2006;45:3503–3506.
33. Taylor SD, Desoky A. Rapid and efficient chemoselective and multiple sulfations of phenols using sulfuryl imidazolium salts. *Tetrahedron Lett.* 2011;52:3353–3357.
34. Ali AM, Hill B, Taylor SD. Trichloroethyl group as a protecting group for sulfonates and its application to the synthesis of a disulfonate analog of the tyrosine sulfated PSGL-143–50 peptide. *J Org Chem.* 2009;74:3583–3586.
35. Ingram LJ, Desoky A, Ali AM, Taylor SD. O- and N-sulfations of carbohydrates using sulfuryl imidazolium salts. *J Org Chem.* 2009;74:6479–6485.
36. Desoky AY, Taylor SD. Multiple and regioselective introduction of protected sulfates into carbohydrates using sulfuryl imidazolium salts. *J Org Chem.* 2009;74:9406–9412.